Search results for "FIBRATE"

showing 10 items of 84 documents

Sensitivity of liver metabolism in jerboa (Jaculus orientalis) to ciprofibrate, a peroxisome proliferator.

2009

International audience; Ciprofibrate is a well-known drug used to normalize lipid parameters and fibrinogen in atherosclerosis patients. In laboratory rodents such as rats or mice, ciprofibrate exhibits peroxisome proliferator activity. However, to date, no clear alterations or side effects caused by ciprofibrate have been noted in humans. In order to further investigate such possible relationships, we studied the effects of sustained ciprofibrate treatment in jerboas (Jaculus orientalis). In these rodents, ciprofibrate does not induce hepatomegaly or promote liver cell DNA replication, confirming that this species more closely resembles humans than do rats or mice. The jerboas were treated…

Cancer Researchmedicine.medical_specialtyD-3-hydroxybutyrate dehydrogenaseDehydrogenaseBiochemistryJaculus orientalischemistry.chemical_compoundciprofibrateantioxidant enzymesInternal medicineGeneticsmedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular Biology[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biologyclinical enzymesMolecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biologysubcellular markerbiologyLiver cellPeroxisomeMalondialdehydeEndocrinologyOncologychemistryCatalasebiology.proteinKetone bodiesMolecular MedicineNAD+ kinaseCiprofibratemedicine.drug
researchProduct

Human HepG2 and rat Fao hepatic-derived cell lines show different responses to ciprofibrate, a peroxisome proliferator: analysis by flow cytometry.

1996

Abstract Peroxisome proliferators, and especially hypolipidemic drugs such as ciprofibrate, are known to be hepatocarcinogens in rodents, but their effect in humans is controversial. In an attempt to investigate the effects of ciprofibrate at a cellular level, the analysis of individual whole cells was performed by flow cytometry on samples from two hepatic-derived cell lines: the rat Fao cell line and the human HepG2 cell line. The increase of light scatter signals in rat Fao cells treated for 3 days with ciprofibrate at 250 μMwas related to modifications of intrinsic cellular parameters, such as size and cytoplasmic granularity. Conversely, no variations appeared in human HepG2-treated ce…

Carcinoma HepatocellularLightPeroxisome ProliferationBiologyCytoplasmic GranulesMicrobodiesFlow cytometryClofibric AcidmedicineTumor Cells CulturedAnimalsHumansScattering RadiationCell SizeHypolipidemic Agentschemistry.chemical_classificationOxidase testmedicine.diagnostic_testCell CycleLiver NeoplasmsFibric AcidsCell BiologyDNA NeoplasmCell cycleFlow CytometryCell biologyRatsEnzymeBiochemistrychemistryLiverCytoplasmCell cultureCiprofibrateOxidoreductasesCell Divisionmedicine.drugExperimental cell research
researchProduct

Stimulation of peroxisomal palmitoyl-CoA oxidase activity by ciprofibrate in hepatic cell lines: comparative studies in Fao, MH1C1 and HepG2 cells.

1993

The response of two rat cell lines, Fao and MH1C1, and one human cell line, HepG2, to the peroxisome proliferator ciprofibrate, was studied. Using a fluorometric assay for palmitoyl-CoA oxidase, the dose- and time-dependent increase of this enzymatic activity was determined. From the lowest concentration (100 microM) stimulation is evident in the two rat cell lines. In the Fao line, the activity was stimulated reaching a seven-fold increase over the control level at 250 microM after 72 h of treatment. In the MH1C1 line, the maximum stimulation, four- to five-fold, was obtained at 250 and 500 microM after 72 h. In the HepG2 cell line, activity increased two-fold at 250 microM after 72 h reac…

Carcinoma HepatocellularStimulationBiologyMicrobodiesClofibric AcidLiver Neoplasms ExperimentalmedicineTumor Cells CulturedAcyl-CoA oxidaseAnimalsHumansHypolipidemic AgentsOxidase testLiver NeoplasmsFibric AcidsCell BiologyGeneral MedicinePeroxisomePalmitoyl-CoA oxidase activityBiochemistryLiverCell cultureHepatic stellate cellCiprofibrateOxidoreductasesmedicine.drugBiology of the cell
researchProduct

Relationship between signal transduction and PPAR alpha-regulated genes of lipid metabolism in rat hepatic-derived Fao cells.

2001

The goal of this study was to characterize phosphorylated proteins and to evaluate the changes in their phosphorylation level under the influence of a peroxisome proliferator (PP) with hypolipidemic activity of the fibrate family. The incubation of rat hepatic derived Fao cells with ciprofibrate leads to an overphosphorylation of proteins, especially one of 85 kDa, indicating that kinase (or phosphatase) activities are modified. Moreover, immunoprecipitation of 32P-labeled cell lysates shows that the nuclear receptor, PP-activated receptor, alpha isoform, can exist in a phosphorylated form, and its phosphorylation is increased by ciprofibrate. This study shows that PP acts at different step…

Cell signalingBiophysicsPeroxisome proliferator-activated receptorReceptors Cytoplasmic and NuclearBiologyBiochemistryCell LinemedicineAnimalschemistry.chemical_classificationKinaseLipid metabolismCell BiologyGeneral MedicineLipid MetabolismRatschemistryBiochemistryNuclear receptorGene Expression RegulationLiverPeroxisome proliferator-activated receptor alphaCiprofibrateSignal transductionmedicine.drugSignal TransductionTranscription FactorsCell biochemistry and biophysics
researchProduct

Rat adrenoleukodystrophy-related (ALDR) gene: full-length cDNA sequence and new insight in expression.

2001

X-linked adrenoleukodystrophy (X-ALD) is an inherited demyelinating disorder due to mutations in the ALD gene, which encodes a peroxisomal ABC half-transporter (ALDP). It has been suggested that ALDP assembles with ALDRP (adrenoleukodystrophy-related protein), a close homologous half-transporter, to form a functional heterodimer. For the first time full-length ALDRP cDNA (5.5 kb) was cloned, and 5' and 3' RACE analysis revealed that alternative usage of polyadenylation sites generates the two transcripts of 3.0 and 5.5 kb observed in the rat in Northern blot analysis. Southern blotting and chromosomal mapping demonstrated one ALDR locus in the rat genome. Characterisation of the 3' flanking…

DNA ComplementaryPolyadenylationMolecular Sequence DataBiophysicsLocus (genetics)BiologyATP Binding Cassette Transporter Subfamily DBiochemistryMiceFenofibrateStructural BiologyComplementary DNAGene expressionGeneticsmedicineAnimalsNorthern blotAmino Acid SequenceCloning MolecularRats WistarAdrenoleukodystrophyGene3' Untranslated RegionsSouthern blotGene LibraryGeneticsBase SequenceBrainChromosome MappingGene Expression Regulation DevelopmentalProteinsmedicine.diseaseMolecular biologyRatsProtein BiosynthesisAdrenoleukodystrophyATP-Binding Cassette Transporters5' Untranslated RegionsBiochimica et biophysica acta
researchProduct

Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision

2008

OBJECTIVE: To assess whether the prescribing pattern of lipid-lowering drugs (LLD) changed after reimbursement criteria revision in a general practice in southern Italy. METHODS: From the Caserta-1 Local Health Service database, 93 general practitioners (GPs) who had consistently sent data about their patients during the years 2003-2005 were recruited. Prevalence of use and incidence of new treatments were calculated for each year, stratified by three drug cohorts: statins, omega-3 fatty acids, and fibrates. Subanalyses by gender, age, and indication of use were performed. RESULTS: Overall, 1-year prevalence of LLD use increased from 2003 to 2004. After reimbursement criteria revision (Nove…

Drug Utilizationmedicine.medical_specialtyPediatricsStatinSettore MED/09 - Medicina Internamedicine.drug_classMEDLINEstatinsInternal medicineFatty Acids Omega-3EpidemiologyHumansMedicinePharmacology (medical)RosuvastatinLipid-lowering drug Statins Omega-3 fatty acids Prevalence of use General practiceClofibrateReimbursementUnsaturated fatty acidHypolipidemic AgentsPharmacologygeneral practiceprevalence of usePrimary Health Careomega-3 fatty acidsbusiness.industryIncidence (epidemiology)General Medicinelipid-lowering drugSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheDrug UtilizationItalyInsurance Health ReimbursementSettore BIO/14 - FarmacologiaHydroxymethylglutaryl-CoA Reductase Inhibitorslipid-lowering drug; statins; omega-3 fatty acids; prevalence of use; general practicebusinessmedicine.drug
researchProduct

Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.

2007

An increasing number of newly developed drugs show bioavailability problems due to poor water solubility. Formulating the drugs as nanosuspensions may help to overcome these problems by increasing saturation solubility and dissolution velocity. In the present study the bioavailability of the poorly soluble fenofibrate following oral administration was investigated in rats. Four formulations were tested: a nanosuspension type DissoCube(R), one solid lipid nanoparticle (SLN) preparation and two suspensions of micronized fenofibrate as reference formulations, one suspension in sirupus simplex and a second in a solution of hydroxyethy-cellulose in physiological saline. Both colloidal drug deliv…

DrugMalemedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalDosage formPharmacokineticsFenofibrateSuspensionsSolid lipid nanoparticlemedicineAnimalsComputer SimulationTissue DistributionSolubilityRats Wistarmedia_commonHypolipidemic AgentsFenofibrateChemistryLipidsBioavailabilityRatsSolubilityDrug deliveryNanoparticlesmedicine.drugAdvanced drug delivery reviews
researchProduct

Hypolipidaemic effects of fenofibrate are not altered by mildronate-mediated normalization of carnitine concentration in rat liver.

1999

The five-fold higher carnitine content in the liver of fenofibrate-treated rats addresses the question about the possible role of this enhancement in the hypolipidaemic effect of the drug and the underlying mechanisms. When fenofibrate was administered with mildronate (a gamma-butyrobetaine hydroxylase inhibitor) in suitable amount, the content in carnitine was found to be normalized in liver. However, triglyceride contents of liver and serum were then at least as low as in rats treated by fenofibrate only. When carnitine concentration was lowered by mildronate to the third of the normal value, a marked increase in triglycerides occurred both in liver and serum, while the five-fold increase…

DrugMalemedicine.medical_specialtymedia_common.quotation_subjectBlood lipidsKetone BodiesBiochemistrychemistry.chemical_compoundFenofibrateInternal medicineCarnitinemedicineAnimalsCarnitineRats WistarMuscle SkeletalBeta oxidationPhospholipidsTriglyceridesmedia_commonHypolipidemic AgentsFenofibrateTriglycerideChemistryMyocardiumGeneral MedicinePeroxisomeRatsEndocrinologyCholesterolBiochemistryLiverKetone bodiesmedicine.drugMethylhydrazinesBiochimie
researchProduct

Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production

2004

Increased Abeta42 production has been linked to the development of Alzheimer disease. We now identify a number of compounds that raise Abeta42. Among the more potent Abeta42-raising agents identified are fenofibrate, an antilipidemic agent, and celecoxib, a COX-2-selective NSAID. Many COX-2-selective NSAIDs tested raised Abeta42, including multiple COX-2-selective derivatives of two Abeta42-lowering NSAIDs. Compounds devoid of COX activity and the endogenous isoprenoids FPP and GGPP also raised Abeta42. These compounds seem to target the gamma-secretase complex, increasing gamma-secretase-catalyzed production of Abeta42 in vitro. Short-term in vivo studies show that two Abeta42-raising comp…

Enzyme-Linked Immunosorbent AssayEndogenyProtein Serine-Threonine KinasesPharmacologyTransfectionMass SpectrometryGeneral Biochemistry Genetics and Molecular BiologyPresenilinCell LineFenofibrateAlzheimer DiseaseIn vivoEndopeptidasesmedicineAspartic Acid EndopeptidasesHumansImmunoprecipitationCyclooxygenase InhibitorsProtein precursorHypolipidemic AgentsSulfonamidesrho-Associated KinasesAmyloid beta-PeptidesFenofibratebusiness.industryAnti-Inflammatory Agents Non-SteroidalIntracellular Signaling Peptides and ProteinsBrainGeneral Medicinemedicine.diseaseIn vitroEnzyme ActivationBiochemistryCelecoxibPyrazolesFemaleAmyloid Precursor Protein SecretasesAlzheimer's diseaserhoA GTP-Binding ProteinbusinessAntilipidemic Agentmedicine.drugNature Medicine
researchProduct

Isolation and characterization of a cDNA encoding rat liver cytosolic epoxide hydrolase and its functional expression in Escherichia coli.

1993

A cDNA of 1992 base pairs encoding the complete rat liver cytosolic epoxide hydrolase has been isolated using a polymerase chain reaction-derived DNA fragment (Arand, M., Knehr, M., Thomas, H., Zeller, H. D., and Oesch, F. (1991) FEBS Lett. 294, 19-22) known to represent the 3'-end of the cytosolic epoxide hydrolase mRNA. Sequence analysis revealed an open reading frame of 1662 nucleotides corresponding to 554 amino acids (M(r) = 62,268). The DNA sequence obtained did not display significant homology to the sequences of microsomal epoxide hydrolase or leukotriene A4 hydrolase or to any other DNA included in the EMBL Data Bank (release 32). On Northern blotting of rat liver RNA, a single mRN…

Epoxide hydrolase 2Male1303 BiochemistryBase pairMolecular Sequence DataRestriction Mapping10050 Institute of Pharmacology and Toxicology610 Medicine & healthBiologyBiochemistryLeukotriene-A4 hydrolase1307 Cell BiologyRats Sprague-Dawleychemistry.chemical_compoundCytosolFenofibrateComplementary DNA1312 Molecular BiologyEscherichia coliAnimalsAmino Acid SequenceCloning MolecularEpoxide hydrolaseMolecular BiologyPeroxisomal targeting signalEpoxide HydrolasesBase SequenceCell BiologyDNABlotting NorthernMolecular biologyRatschemistryBiochemistryLiverMicrosomal epoxide hydrolase570 Life sciences; biologyDNAThe Journal of biological chemistry
researchProduct